This content is only available within our institutional offering.
30 Sep 2019
Interims 1H19: Unlocking Value in the Pipeline
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Interims 1H19: Unlocking Value in the Pipeline
ImmuPharma plc (IMM:LON) | 2.1 0 (-2.5%) | Mkt Cap: 8.85m
- Published:
30 Sep 2019 -
Author:
Dr. Navid Malik -
Pages:
4
ImmuPharma released its interim results this morning. The results statement highlights key activities around the Company’s lead drug, Lupuzor including: the successful conclusion of the open label study, meeting its primary endpoint (safety), and the important work in fully understanding the Phase III data from the Lupuzor study which concluded in H1 2018. Taken together, the overall data (incl. the European data from the Phase III clinical trial) around Lupuzor continues to mature positively. Against a backdrop of progress in the Lupus field as highlighted in our update notes (See TLSD reports: 09/09/2019 and 23/09/2019), we believe the company is making significant progress in fully exploiting the potential for Lupuzor as a novel therapeutic; this is strengthened and complemented by recent updates by competitors in the market. Further value is being generated as broader pipeline products such as Ureka Sarl (platform peptide) and Elro Pharma (Nucant), create further value for investors through a potential partnering or divestment approach. Importantly, given the clinical data behind Lupuzor and its unique mechanism of action, there are other indications that will be available for development within the auto-immune space for Lupuzor beyond Lupus. We believe that the coming months will further demonstrate the progress the company is making towards these goals. BUY.